JP2019201643A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019201643A5 JP2019201643A5 JP2019111990A JP2019111990A JP2019201643A5 JP 2019201643 A5 JP2019201643 A5 JP 2019201643A5 JP 2019111990 A JP2019111990 A JP 2019111990A JP 2019111990 A JP2019111990 A JP 2019111990A JP 2019201643 A5 JP2019201643 A5 JP 2019201643A5
- Authority
- JP
- Japan
- Prior art keywords
- isolated antibody
- functional fragment
- antibody
- domain
- collection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000012634 fragment Substances 0.000 claims 13
- 150000007523 nucleic acids Chemical class 0.000 claims 8
- 102000039446 nucleic acids Human genes 0.000 claims 8
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 239000013598 vector Substances 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 2
- 230000004927 fusion Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 1
- 241000283984 Rodentia Species 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000004602 germ cell Anatomy 0.000 claims 1
- 239000000411 inducer Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021169020A JP2022028659A (ja) | 2013-06-26 | 2021-10-14 | 新規抗体フレームワーク |
| JP2023199881A JP2024026176A (ja) | 2013-06-26 | 2023-11-27 | 新規抗体フレームワーク |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13003264 | 2013-06-26 | ||
| EP13003264.2 | 2013-06-26 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016522319A Division JP6708544B2 (ja) | 2013-06-26 | 2014-06-26 | 新規抗体フレームワーク |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021169020A Division JP2022028659A (ja) | 2013-06-26 | 2021-10-14 | 新規抗体フレームワーク |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019201643A JP2019201643A (ja) | 2019-11-28 |
| JP2019201643A5 true JP2019201643A5 (enExample) | 2020-01-16 |
Family
ID=48699516
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016522319A Active JP6708544B2 (ja) | 2013-06-26 | 2014-06-26 | 新規抗体フレームワーク |
| JP2019111990A Withdrawn JP2019201643A (ja) | 2013-06-26 | 2019-06-17 | 新規抗体フレームワーク |
| JP2021169020A Pending JP2022028659A (ja) | 2013-06-26 | 2021-10-14 | 新規抗体フレームワーク |
| JP2023199881A Pending JP2024026176A (ja) | 2013-06-26 | 2023-11-27 | 新規抗体フレームワーク |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016522319A Active JP6708544B2 (ja) | 2013-06-26 | 2014-06-26 | 新規抗体フレームワーク |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021169020A Pending JP2022028659A (ja) | 2013-06-26 | 2021-10-14 | 新規抗体フレームワーク |
| JP2023199881A Pending JP2024026176A (ja) | 2013-06-26 | 2023-11-27 | 新規抗体フレームワーク |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10174102B2 (enExample) |
| EP (1) | EP3013864A1 (enExample) |
| JP (4) | JP6708544B2 (enExample) |
| KR (4) | KR20210097829A (enExample) |
| CN (2) | CN113943366B (enExample) |
| AU (2) | AU2014301629B2 (enExample) |
| CA (1) | CA2914829A1 (enExample) |
| HK (1) | HK1218549A1 (enExample) |
| IL (3) | IL243311B (enExample) |
| NZ (1) | NZ714320A (enExample) |
| SG (2) | SG11201509899PA (enExample) |
| WO (1) | WO2014206561A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL243311B (en) | 2013-06-26 | 2022-07-01 | Numab Therapeutics AG | New frameworks for antibodies |
| MX395604B (es) | 2015-06-15 | 2025-03-25 | Numab Therapeutics AG | Formato de anticuerpo multiespecífico heterodimérico. |
| KR20180111870A (ko) | 2016-02-25 | 2018-10-11 | 셀 메디카 스위처란트 아게 | Pd-l1에 대한 결합 성분 |
| US10787508B2 (en) | 2016-03-17 | 2020-09-29 | Numab Innovation Ag | Anti-TNFα-antibodies and functional fragments thereof |
| BR112018017165A2 (pt) | 2016-03-17 | 2019-01-02 | Numab Innovation Ag | anticorpos anti-tnf-alfa e fragmentos funcionais dos mesmos |
| JP6978427B2 (ja) | 2016-03-17 | 2021-12-08 | ヌマブ セラピューティクス アクチェンゲゼルシャフト | 抗ＴＮＦα抗体とその機能性フラグメント |
| EP3219726B1 (en) | 2016-03-17 | 2020-12-02 | Tillotts Pharma AG | Anti-tnf alpha-antibodies and functional fragments thereof |
| RS61412B1 (sr) | 2016-03-17 | 2021-03-31 | Tillotts Pharma Ag | Anti-tnf alfa-antitela i njihovi funkcionalni fragmenti |
| GB201621591D0 (en) * | 2016-12-19 | 2017-02-01 | Ucb Biopharma Sprl | Antibody molecules and method |
| EP3634998B8 (en) | 2017-06-05 | 2025-04-09 | Numab Therapeutics AG | Anti-cd3 epsilon antibodies |
| WO2018224441A1 (en) | 2017-06-05 | 2018-12-13 | Numab Innovation Ag | Novel anti-cd3 antibodies |
| JP7130678B2 (ja) | 2017-06-05 | 2022-09-05 | ヌマブ セラピューティクス アクチェンゲゼルシャフト | 新規抗ｈｓａ抗体 |
| US12098203B2 (en) | 2017-06-05 | 2024-09-24 | Numab Therapeutics AG | Hetero-dimeric multi-specific antibody format targeting at least CD3 and HSA |
| WO2018224439A1 (en) | 2017-06-05 | 2018-12-13 | Numab Innovation Ag | Novel anti-hsa antibodies |
| EP3645048A4 (en) * | 2017-06-25 | 2021-06-16 | Systimmune, Inc. | MULTISPECIFIC ANTIBODIES AND THE METHOD OF MANUFACTURING AND USING THEREOF |
| US11787863B2 (en) | 2017-06-25 | 2023-10-17 | Systimmune, Inc. | Multi-specific antibodies and methods of making and using thereof |
| EP3459968A1 (en) | 2017-09-20 | 2019-03-27 | Numab Innovation AG | Novel stable antibody variable domain framework combinations |
| IL320091A (en) | 2019-01-31 | 2025-06-01 | Numab Therapeutics AG | Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof |
| EP3689907A1 (en) | 2019-01-31 | 2020-08-05 | Numab Therapeutics AG | Antibodies targeting il-17a and methods of use thereof |
| JP2024501884A (ja) * | 2020-12-30 | 2024-01-16 | アセンド バイオテクノロジー インク | ヒトｍａｃ－１に対するモノクローナル抗体及びその使用 |
| TW202246319A (zh) | 2021-02-12 | 2022-12-01 | 德商百靈佳殷格翰國際股份有限公司 | 補體c3抗原結合蛋白 |
| JP2024509971A (ja) | 2021-03-11 | 2024-03-05 | アイジェニックス， インコーポレイテッド | アレルギー応答を予測するための方法およびシステム |
| AU2022420788A1 (en) | 2021-12-22 | 2024-05-16 | Boehringer Ingelheim International Gmbh | Anti-c3 antibodies and antigen-binding fragments thereof and their uses for treating eye or ocular diseases |
| WO2024098026A2 (en) * | 2022-11-04 | 2024-05-10 | Mink Therapeutics, Inc. | B-cell maturation antigen (bcma) chimeric antigen receptor invariant natural killer t cells and uses thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE19819846B4 (de) | 1998-05-05 | 2016-11-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Multivalente Antikörper-Konstrukte |
| AU2003259718A1 (en) | 2003-08-07 | 2005-03-07 | Epitomics, Inc. | Methods for humanizing rabbit monoclonal antibodies |
| WO2008004834A1 (en) | 2006-07-06 | 2008-01-10 | Isu Abxis Co., Ltd | Humanized monoclonal antibody highly binding to epidermal growth factor receptor, egf receptor |
| FR2910896B1 (fr) * | 2006-12-29 | 2012-11-16 | Lab Francais Du Fractionnement | Anticorps monoclonal dirige contre le recepteur humain des ldl |
| KR20170036814A (ko) | 2007-05-21 | 2017-04-03 | 앨더바이오 홀딩스 엘엘씨 | 신규한 래빗 항체 인간화 방법 및 인간화된 래빗 항체 |
| DK2158315T3 (en) | 2007-06-25 | 2016-06-06 | Esbatech Alcon Biomed Res Unit | Methods of modifying antibodies and modified antibodies with improved functional properties |
| RU2653753C1 (ru) | 2008-06-25 | 2018-05-14 | ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи | СТАБИЛЬНЫЕ И РАСТВОРИМЫЕ АНТИТЕЛА, ИНГИБИРУЮЩИЕ TNFα |
| HUE032894T2 (hu) * | 2008-06-25 | 2017-11-28 | Esbatech Alcon Biomed Res Unit | VEGF-gátló, stabilis és oldható antitestek |
| CN104004094B (zh) | 2008-06-25 | 2017-09-22 | 艾斯巴技术-诺华有限责任公司 | 使用通用抗体构架进行的兔抗体的人源化 |
| WO2010144780A1 (en) | 2009-06-12 | 2010-12-16 | University Of Kansas | Compositions and methods for establishing and maintaining stem cells in an undifferentiated state |
| EP2563812A4 (en) * | 2010-04-30 | 2016-01-13 | Alexion Pharma Inc | ANTIBODIES WITH REDUCED IMMUNOGENITY IN HUMANS |
| US20140213459A1 (en) * | 2011-05-27 | 2014-07-31 | Roland Beckmann | Antibodies with improved folding stability |
| IL243311B (en) | 2013-06-26 | 2022-07-01 | Numab Therapeutics AG | New frameworks for antibodies |
| EP3459968A1 (en) | 2017-09-20 | 2019-03-27 | Numab Innovation AG | Novel stable antibody variable domain framework combinations |
-
2014
- 2014-06-26 IL IL243311A patent/IL243311B/en unknown
- 2014-06-26 KR KR1020217024096A patent/KR20210097829A/ko not_active Ceased
- 2014-06-26 SG SG11201509899PA patent/SG11201509899PA/en unknown
- 2014-06-26 CA CA2914829A patent/CA2914829A1/en active Pending
- 2014-06-26 US US14/900,550 patent/US10174102B2/en active Active
- 2014-06-26 CN CN202111136784.7A patent/CN113943366B/zh active Active
- 2014-06-26 EP EP14737144.7A patent/EP3013864A1/en active Pending
- 2014-06-26 NZ NZ714320A patent/NZ714320A/en unknown
- 2014-06-26 HK HK16106054.2A patent/HK1218549A1/zh unknown
- 2014-06-26 SG SG10201811017QA patent/SG10201811017QA/en unknown
- 2014-06-26 KR KR1020237043185A patent/KR20240000622A/ko active Pending
- 2014-06-26 IL IL293477A patent/IL293477B2/en unknown
- 2014-06-26 JP JP2016522319A patent/JP6708544B2/ja active Active
- 2014-06-26 KR KR1020227006072A patent/KR20220029763A/ko not_active Ceased
- 2014-06-26 IL IL313351A patent/IL313351B1/en unknown
- 2014-06-26 WO PCT/EP2014/001730 patent/WO2014206561A1/en not_active Ceased
- 2014-06-26 CN CN201480036689.1A patent/CN105579472B/zh active Active
- 2014-06-26 KR KR1020167001339A patent/KR102286053B1/ko active Active
- 2014-06-26 AU AU2014301629A patent/AU2014301629B2/en active Active
-
2018
- 2018-10-10 US US16/156,036 patent/US11427628B2/en active Active
-
2019
- 2019-06-17 JP JP2019111990A patent/JP2019201643A/ja not_active Withdrawn
-
2020
- 2020-04-27 AU AU2020202770A patent/AU2020202770B2/en active Active
-
2021
- 2021-10-14 JP JP2021169020A patent/JP2022028659A/ja active Pending
-
2022
- 2022-08-29 US US17/822,959 patent/US20230212265A1/en active Pending
-
2023
- 2023-11-27 JP JP2023199881A patent/JP2024026176A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019201643A5 (enExample) | ||
| HRP20251150T1 (hr) | Anti-her2 protutijela i postupci uporabe | |
| JP2019501883A5 (enExample) | ||
| JP2020525032A5 (enExample) | ||
| JP2018522541A5 (enExample) | ||
| HRP20231134T1 (hr) | Humanizirana i afinitetno zrela protutijela na fcrh5 i postupci za uporabu | |
| HRP20200583T1 (hr) | Protutijela koja neutraliziraju gp120 i njihova upotreba | |
| JP2019054802A5 (enExample) | ||
| JP2018035138A5 (enExample) | ||
| JP2020535799A5 (enExample) | ||
| JP2018521638A5 (enExample) | ||
| JP2020504101A5 (enExample) | ||
| CN112574307A (zh) | 抗人Claudin18.2抗体及其应用 | |
| JP2021500853A5 (enExample) | ||
| JP2018506961A5 (enExample) | ||
| JP2017514461A5 (enExample) | ||
| FI3322727T3 (fi) | Humanisoituja tai kimeerisiä CD3-vasta-aineita | |
| JP2015163068A5 (enExample) | ||
| JP2020514277A5 (enExample) | ||
| JP2019527553A5 (enExample) | ||
| JP2018526981A5 (enExample) | ||
| JP2016533763A5 (ja) | ヒトｐｄ−１に特異的に結合する抗体抗原結合ドメインおよびそれを含む医薬組成物 | |
| JP2018510636A5 (enExample) | ||
| JP2013198490A5 (enExample) | ||
| RU2017134495A (ru) | Антитела к альфа-рецептору собачьего интерлейкина-4 |